MCID: ONC002
MIFTS: 50

Onchocerciasis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Onchocerciasis

MalaCards integrated aliases for Onchocerciasis:

Name: Onchocerciasis 12 75 53 59 55 3 44 15 17 72 33
River Blindness 53 3
Infection by Onchocerca Volvulus 12
Onchocerca Volvulus Infection 12
Onchocerciasis, Ocular 72
Robles' Disease 53
Volvulosis 12

Characteristics:

Orphanet epidemiological data:

59
onchocerciasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11678
ICD9CM 35 125.3
MeSH 44 D009855
NCIt 50 C34861
SNOMED-CT 68 38539003
ICD10 33 B73
MESH via Orphanet 45 D009855 D015827
ICD10 via Orphanet 34 B73
UMLS via Orphanet 73 C0029001 C0029002
Orphanet 59 ORPHA2737
UMLS 72 C0029001 C0029002

Summaries for Onchocerciasis

NIH Rare Diseases : 53 Onchocerciasis is a rare tropical parasitic disease transmitted by a black fly. Infection by the parasite can cause eye and skin problems. In humans, the parasitic worms live under the skin (subcutaneous nodules) and produce larvae (microfilariae). The larvae are found throughout the body, but especially in the skin and eyes. Repeated bites by infected flies increase the number of adult worms and larvae. Chronic skin onchocerciasis (onchodermatitis) causes itching, a rash with small pimples (papular rash), scarring, and thickened, leathery skin (lichenification). Other symptoms may develop over time and might include saggy skin (such as ''hanging groin''), patchy areas of much lighter colored skin (leopard skin), ichthyosis-like lesions (''lizard skin''), darkening of the skin, and very severe itching. The eye infection is known as river blindness because the blackfly carrying the parasite lives near fast-flowing waters. Symptoms of an eye infection may include itchy eyes, red eyes, and sensitivity to light (photophobia). In some cases, the larvae may infect the optic nerve. As the common name suggests, infection of the eye by onchocerciasis can lead to vision loss and eventually blindness. The disease is caused by the parasitic worm Onchocerca volvulus and is transmitted by the bite of an infected black fly. About 90% of the cases occur in Africa. Treatment aims to remove the larvae (microfilariae), to improve symptoms, to prevent progression of eye lesions, and to stop the parasite from being passed back to black flies so other people do not become infected. Medications include an anti-parasitic known as ivermectin, antibiotics such as rifampin, azithromycin, and doxycycline, and, another recently approved anti-parasitic drug, Moxidectin.

MalaCards based summary : Onchocerciasis, also known as river blindness, is related to filariasis and filarial elephantiasis. An important gene associated with Onchocerciasis is RBP3 (Retinol Binding Protein 3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Diethylcarbamazine and Ivermectin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes.

Disease Ontology : 12 A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.

CDC : 3 Onchocerciasis, or River Blindness, is a neglected tropical disease (NTD) caused by the parasitic worm Onchocerca volvulus. It is transmitted through repeated bites by blackflies of the genus Simulium. The disease is called River Blindness because the blackfly that transmits the infection lives and breeds near fast-flowing streams and rivers and the infection can result in blindness. In addition to visual impairment or blindness, onchocerciasis causes skin disease, including nodules under the skin or debilitating itching. Worldwide onchocerciasis is second only to trachoma as an infectious cause of blindness.

Wikipedia : 75 Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm... more...

Related Diseases for Onchocerciasis

Diseases related to Onchocerciasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 272)
# Related Disease Score Top Affiliating Genes
1 filariasis 31.6 IL5 IL2 CCL5
2 filarial elephantiasis 31.4 SRCIN1 IL5 IL4
3 elephantiasis 31.3 SRCIN1 RNASE3
4 intestinal volvulus 31.3 SRCIN1 IL5 CALR
5 chorioretinitis 31.2 SRCIN1 RBP3
6 cytokine deficiency 30.6 IL5 IL13
7 scleritis 30.6 IL5 IL4
8 autoimmune disease 30.6 RBP3 IL4 IL2
9 ascaris lumbricoides infection 30.4 IL5 IL13
10 wells syndrome 30.4 RNASE3 IL5 IL2
11 posterior uveitis 30.2 RBP3 IL2
12 tetanus 30.1 IL5 IL4 IL2 IL13
13 dermatitis 30.1 IL5 IL4 IL13 CCL11
14 schistosomiasis 30.0 RNASE3 IL5 IL4 IL2 IL13
15 strongyloidiasis 30.0 IL5 IL13 CCL11
16 skin disease 29.9 RNASE3 IL5 IL4 IL13 CCL11
17 immune deficiency disease 29.8 IL4 IL2 IL13
18 ige responsiveness, atopic 29.7 RNASE3 IL5 IL4 IL13
19 urinary schistosomiasis 29.4 RNASE3 IL5 IL4 IL13 EPX
20 trypanosomiasis 29.4 IL4 IL2 CCL5 CALR
21 hypereosinophilic syndrome 29.4 RNASE3 IL5 IL4 IL13 EPX CCL11
22 leishmaniasis 29.3 MPI IL5 IL4 IL13
23 intestinal schistosomiasis 29.2 SRCIN1 IL5 IL4 IL13
24 allergic conjunctivitis 28.9 RNASE3 IL5 IL4 IL13 CCL11
25 parasitic helminthiasis infectious disease 28.7 SRCIN1 RNASE3 IL5 IL4 IL2 IL13
26 malaria 28.5 IL5 IL4 IL2 IL13 CCL5 CCL11
27 keratoconjunctivitis 28.4 RNASE3 IL5 IL4 IL2 IL13 CCL11
28 conjunctivitis 28.4 RNASE3 IL5 IL4 IL2 IL13 EPX
29 pulmonary eosinophilia 27.9 RNASE3 IL5 IL4 IL13 EPX CCL5
30 allergic hypersensitivity disease 27.8 RNASE3 IL5 IL4 IL13 EPX CCL7
31 dermatitis, atopic 27.4 RNASE3 IL5 IL4 IL2 IL13 EPX
32 loiasis 11.7
33 yemenite deaf-blind hypopigmentation syndrome 11.0
34 keratitis, hereditary 10.7
35 virus associated hemophagocytic syndrome 10.6 IL4 IL2
36 egg allergy 10.6 IL5 IL4
37 loeffler endocarditis 10.6 RNASE3 IL5
38 autoimmune vasculitis 10.6 IL4 IL2
39 epilepsy 10.6
40 sulfamethoxazole allergy 10.6 IL5 IL4
41 trichinosis 10.6 IL5 IL4
42 jak3-deficient severe combined immunodeficiency 10.6 IL4 IL2
43 sclerosing keratitis 10.6
44 cow milk allergy 10.5 RNASE3 IL5
45 non-suppurative otitis media 10.5 IL5 IL4
46 papillary conjunctivitis 10.5 IL4 CCL11
47 eye disease 10.5
48 punctate epithelial keratoconjunctivitis 10.5
49 anterior uveitis 10.5
50 eosinophilic granuloma 10.5 RNASE3 EPX

Graphical network of the top 20 diseases related to Onchocerciasis:



Diseases related to Onchocerciasis

Symptoms & Phenotypes for Onchocerciasis

Drugs & Therapeutics for Onchocerciasis

Drugs for Onchocerciasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
2
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
3 Anthelmintics Phase 4
4 Lipoxygenase Inhibitors Phase 4
5 Antiparasitic Agents Phase 4
6 Anti-Infective Agents Phase 4
7 Anticonvulsants Phase 4
8
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
9 Vitamins Phase 3
10 Tubulin Modulators Phase 3
11 Antimitotic Agents Phase 3
12 Antiprotozoal Agents Phase 3
13 Milbemycin Phase 3
14
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
15
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
16
Rifampicin Approved Phase 2 13292-46-1 5381226 5458213
17
Azithromycin Approved Phase 2 83905-01-5 447043 55185
18
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
20
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
21
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
22 Neurotransmitter Agents Phase 2
23 Sodium Channel Blockers Phase 2
24 Tranquilizing Agents Phase 2
25 Central Nervous System Depressants Phase 2
26 Micronutrients Phase 2
27 Trace Elements Phase 2
28 GABA Agents Phase 2
29 Diuretics, Potassium Sparing Phase 2
30 Antimanic Agents Phase 2
31 Vitamin B9 Phase 2
32 Vitamin B Complex Phase 2
33 Folate Phase 2
34 Vitamin B 6 Phase 2
35 Nutrients Phase 2
36 Psychotropic Drugs Phase 2
37 Anti-Bacterial Agents Phase 2
38 Antitubercular Agents Phase 2
39 Antibiotics, Antitubercular Phase 2
40 Nucleic Acid Synthesis Inhibitors Phase 2
41 Cytochrome P-450 CYP3A Inducers Phase 2
42 Cytochrome P-450 Enzyme Inducers Phase 2
43 Antimalarials Phase 2
44 Artemisinins Phase 2
45 Artemisinine Phase 2
46 Adjuvants, Immunologic Phase 2
47 Immunologic Factors Phase 2
48 Antirheumatic Agents Phase 2
49 Imatinib Mesylate Phase 2 220127-57-1 123596
50 Protein Kinase Inhibitors Phase 2

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial Completed NCT03052998 Phase 4 Ivermectin
2 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
3 OAETREAT Extra Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy: a Active, not recruiting NCT03852303 Phase 4 ivermectin
4 A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
5 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis in the Volta Region, Ghana. Completed NCT02078024 Phase 3 IVM plus ALB;IVM
6 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
7 A Randomized, Double Blind, Parallel Trial in the Democratic Republic of Congo (DRC) Comparing the Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Treatment of Onchocerciasis Not yet recruiting NCT03876262 Phase 3 Moxidectin;Ivermectin
8 Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012 Unknown status NCT01730313 Phase 2 Pyridoxine;Sodium Valproate;Phenytoin;Placebo
9 A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
10 Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala Completed NCT00127504 Phase 2 Rifampin;Azithromycin
11 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
12 Randomized Clinical Trial, Double-blind, Single-dose Drug and Escalating Infection Intensities, Evaluating the Safety and Efficacy of Moxidectin 2 mg, Ivermectin-controlled, in Loa Loa Microfilaremic Patients Not yet recruiting NCT04049851 Phase 2 Moxidectin 2 MG Oral Tablet;Ivermectin 3Mg Tab;Placebo oral tablet
13 Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients Not yet recruiting NCT04049630 Phase 2 LEV 1 mg/kg;LEV 1,5 mg/kg;Placebo
14 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
15 A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection Withdrawn NCT01035619 Phase 2 moxidectin
16 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Potential Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers Completed NCT03012828 Phase 1 Moxidectin
17 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
18 An Open-label Study of the Pharmacokinetics and Safety of a Single Dose of Moxidectin Per Oral in Subjects Aged 4 to 17 Years With (or at Risk of) Onchocerciasis to Identify an Optimal Dose for Treatment of Children 4 to 11 Years Not yet recruiting NCT03962062 Phase 1 Moxidectin
19 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
20 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
21 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
22 Community-Directed Treatment in the Control of Soil-Transmitted Helminths Among Children Aged 12-59 Months in Mazabuka District of Zambia Completed NCT00349323
23 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
24 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
25 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
26 Veron Scabies Education and Eradication Program Completed NCT00604084 Ivermectin;Permethrin 5% lotion
27 Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District Recruiting NCT03653975
28 Host Response to Infection and Treatment in the Filarial Diseases of Humans Recruiting NCT00001230
29 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Recruiting NCT03683745
30 Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis Active, not recruiting NCT03517462 Ivermectin 3Mg Tab
31 Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa Not yet recruiting NCT04035174

Search NIH Clinical Center for Onchocerciasis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Ivermectin
Ivermectin

Cochrane evidence based reviews: onchocerciasis

Genetic Tests for Onchocerciasis

Anatomical Context for Onchocerciasis

MalaCards organs/tissues related to Onchocerciasis:

41
Skin, Eye, Testes, Neutrophil, T Cells, Lymph Node, Breast

Publications for Onchocerciasis

Articles related to Onchocerciasis:

(show top 50) (show all 3609)
# Title Authors PMID Year
1
Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy. 9 38
17302900 2007
2
Genetic polymorphism of the beta-tubulin gene of Onchocerca volvulus in ivermectin naïve patients from Cameroon, and its relationship with fertility of the worms. 9 38
16197589 2006
3
Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). 9 38
12443893 2002
4
Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. 9 38
11169280 2000
5
Pathophysiological roles of calreticulin in autoimmune disease. 9 38
10320638 1999
6
Eosinophils, eosinophil cationic protein and eosinophil-derived neurotoxin in serum and urine of patients with onchocerciasis coinfected with intestinal nematodes and in urinary schistosomiasis. 9 38
10206116 1999
7
Characterization of human immune responses to the cytosolic superoxide dismutase and glutathione S-transferase from Onchocerca volvulus. 9 38
9294549 1997
8
The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection. 9 38
9176114 1997
9
Serum levels of eosinophil cationic protein, eosinophil-derived neurotoxin and myeloperoxidase in infections with filariae and schistosomes. 9 38
9025985 1996
10
Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis. 9 38
8627086 1996
11
Epitopes of the Onchocerca volvulus RAL1 antigen, a member of the calreticulin family of proteins, recognized by sera from patients with onchocerciasis. 9 38
7520419 1994
12
A 16mer peptide of the human autoantigen calreticulin is a most prominent HLA-DR4Dw4-associated self-peptide. 9 38
7836063 1994
13
Regulation of IL-5 in onchocerciasis. A critical role for IL-2. 9 38
8099937 1993
14
Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases. 9 38
7680295 1993
15
Serological cross-reactivity between a human Ro/SS-A autoantigen (calreticulin) and the lambda Ral-1 antigen of Onchocerca volvulus. 9 38
1602002 1992
16
Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis. 9 38
1918387 1991
17
Analysis of aqueous humour in ocular onchocerciasis. 9 38
2036808 1991
18
Cell-mediated immunity against human retinal extract, S-antigen, and interphotoreceptor retinoid binding protein in onchocercal chorioretinopathy. 9 38
2210999 1990
19
Humoral autoimmune response against S-antigen and IRBP in ocular onchocerciasis. 9 38
2365568 1990
20
Humoral and cell-mediated immune response against human retinal antigens in relation to ocular onchocerciasis. 9 38
2378211 1990
21
The Elimination of Neglected Tropical Diseases (NTDs): A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions. 38
31402376 2019
22
Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo. 38
31420005 2019
23
Ivermectin: From theory to clinical application. 38
31071469 2019
24
Increased cost-benefit of strengthening onchocerciasis elimination efforts in areas with high onchocerciasis-associated epilepsy. 38
31393635 2019
25
Ivermectin Impairs the Development of Sexual and Asexual Stages of Plasmodium falciparum In Vitro. 38
31109978 2019
26
Optimization and evaluation of the Esperanza Window Trap to reduce biting rates of Simulium damnosum sensu lato in Northern Uganda. 38
31310607 2019
27
From river blindness to river epilepsy: Implications for onchocerciasis elimination programmes. 38
31318857 2019
28
Identification and characterization of the Onchocerca volvulus Excretory Secretory Product Ov28CRP, a putative GM2 activator protein. 38
31329585 2019
29
Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa. 38
31269966 2019
30
Elimination of onchocerciasis in Africa by 2025: the need for a broad perspective. 38
31303176 2019
31
Economic evaluations of onchocerciasis interventions: a systematic review and research needs. 38
31013395 2019
32
Development and validation of an Onchocerca ochengi adult male worm gerbil model for macrofilaricidal drug screening. 38
31260456 2019
33
Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density. 38
31314757 2019
34
The need for evidence-based strategies and tools for onchocerciasis elimination in Africa. 38
31303174 2019
35
The positive influence the Onchocerciasis Elimination Program for the Americas has had on Africa programs. 38
31303175 2019
36
Projected number of people with onchocerciasis-loiasis co-infection in Africa, 1995 to 2025. 38
31304961 2019
37
Community Participation in and Perception of Community-Directed Treatment with Ivermectin in Kinshasa, DRC. 38
31330958 2019
38
A much-needed advance in the diagnosis of River Blindness. 38
31201417 2019
39
Characterisation of a novel glycosylated glutathione transferase of Onchocerca ochengi, closest relative of the human river blindness parasite. 38
31190665 2019
40
Neglected Tropical Diseases: The Potential Application to Monitoring by microRNAs in the Real World. 38
31218967 2019
41
Review of the National Program for Onchocerciasis Control in the Democratic Republic of the Congo. 38
31200509 2019
42
Development of a High-Throughput Cytometric Screen to Identify Anti- Wolbachia Compounds: The Power of Public-Private Partnership. 38
30958712 2019
43
Discovery of Kirromycins with Anti- Wolbachia Activity from Streptomyces sp. CB00686. 38
31074963 2019
44
"Those who died are the ones that are cured". Walking the political tightrope of Nodding Syndrome in northern Uganda: Emerging challenges for research and policy. 38
31220081 2019
45
Integrating multiple biomarkers to increase sensitivity for the detection of Onchocerca volvulus infection. 38
31201416 2019
46
Low ivermectin use among 5- to 6-year-old children: observations from door-to-door surveys in onchocerciasis-endemic regions in Africa. 38
31251354 2019
47
A test-and-not-treat strategy for onchocerciasis elimination in Loa loa co-endemic areas: cost analysis of a pilot in the Soa health district, Cameroon. 38
31165855 2019
48
Genomic analyses of aminoacyl tRNA synthetases from human-infecting helminths. 38
31046663 2019
49
Emerging Resistance of Neglected Tropical Diseases: A Scoping Review of the Literature. 38
31151318 2019
50
Stigma and epilepsy in onchocerciasis-endemic regions in Africa: a review and recommendations from the onchocerciasis-associated epilepsy working group. 38
31109376 2019

Variations for Onchocerciasis

Expression for Onchocerciasis

Search GEO for disease gene expression data for Onchocerciasis.

Pathways for Onchocerciasis

Pathways related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 RNASE3 IL5 IL4 IL2 IL13 EPX
2
Show member pathways
13.53 IL5 IL4 IL2 IL13 CCL7 CCL5
3
Show member pathways
13.37 IL5 IL4 IL2 IL13 CCL7 CCL5
4
Show member pathways
13.25 IL5 IL4 IL2 IL13 CCL7 CCL5
5
Show member pathways
13.2 IL5 IL4 IL2 IL13 CCL5 CCL11
6
Show member pathways
13.13 IL5 IL4 IL2 IL13 CCL7 CCL5
7 12.68 IL5 IL4 IL2 IL13
8
Show member pathways
12.6 RNASE3 IL5 IL4 IL2 IL13 EPX
9
Show member pathways
12.46 IL5 IL4 IL2 IL13
10
Show member pathways
12.26 IL5 IL4 IL2 IL13
11
Show member pathways
12.21 IL5 IL4 IL13 CCL7 CCL11
12
Show member pathways
12.14 CCL7 CCL5 CCL11
13
Show member pathways
12.13 IL5 IL4 IL2 IL13
14
Show member pathways
11.91 IL5 IL2 IL13
15 11.88 IL5 IL4 IL2
16
Show member pathways
11.88 IL5 IL4 IL2 IL13 CCL7 CCL5
17 11.86 IL4 IL13 CCL11
18 11.73 IL5 IL4 IL2 IL13
19 11.7 IL5 IL4 IL2 IL13
20
Show member pathways
11.64 IL5 IL4 IL2
21 11.62 IL4 IL2 IL13 CCL5 CCL11
22 11.55 IL5 IL4 CCL11
23 11.43 IL4 IL13 CCL5
24 11.35 IL5 IL4 IL13 CCL5 CCL11
25 11.24 IL5 IL4 IL2
26 11.22 IL5 IL4 IL13
27 11.2 IL5 IL4 IL2 IL13
28 11.12 IL5 IL4 IL2 IL13
29 11.1 IL2 IL13
30 11.02 IL5 IL4 IL2 IL13 CCL11
31 10.9 IL5 IL4 IL2 IL13 CCL7 CCL5
32 10.4 IL5 IL4 IL2 IL13 CCL7 CCL5

GO Terms for Onchocerciasis

Cellular components related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 RNASE3 RBP3 IL5 IL4 IL2 IL13
2 extracellular space GO:0005615 9.36 RNASE3 RBP3 IL5 IL4 IL2 IL13
3 cell GO:0005623 9.33 IL2 CCL7 CCL11

Biological processes related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.83 IL5 IL13 CCL7 CCL5 CCL11
2 chemotaxis GO:0006935 9.77 CCL7 CCL5 CCL11
3 cellular response to tumor necrosis factor GO:0071356 9.76 CCL7 CCL5 CCL11
4 cellular response to interferon-gamma GO:0071346 9.74 CCL7 CCL5 CCL11
5 neutrophil chemotaxis GO:0030593 9.72 CCL7 CCL5 CCL11
6 cellular response to interleukin-1 GO:0071347 9.71 CCL7 CCL5 CCL11
7 chemokine-mediated signaling pathway GO:0070098 9.7 CCL7 CCL5 CCL11
8 positive regulation of T cell proliferation GO:0042102 9.67 IL4 IL2 CCL5
9 monocyte chemotaxis GO:0002548 9.65 CCL7 CCL5 CCL11
10 cellular calcium ion homeostasis GO:0006874 9.62 CCL7 CCL5 CCL11 CALR
11 positive regulation of JAK-STAT cascade GO:0046427 9.61 IL5 CCL5
12 positive regulation of T cell differentiation GO:0045582 9.59 IL4 IL2
13 positive regulation of immunoglobulin secretion GO:0051024 9.58 IL5 IL2
14 lymphocyte chemotaxis GO:0048247 9.58 CCL7 CCL5 CCL11
15 positive regulation of isotype switching to IgG isotypes GO:0048304 9.56 IL4 IL2
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 IL4 IL2 IL13 CCL5
17 eosinophil chemotaxis GO:0048245 9.54 CCL7 CCL5 CCL11
18 positive regulation of natural killer cell chemotaxis GO:2000503 9.51 CCL7 CCL5
19 negative regulation of complement-dependent cytotoxicity GO:1903660 9.46 IL4 IL13
20 positive regulation of B cell proliferation GO:0030890 9.46 IL5 IL4 IL2 IL13
21 cytokine-mediated signaling pathway GO:0019221 9.43 IL5 IL4 IL2 IL13 CCL5 CCL11
22 immune response GO:0006955 9.17 IL5 IL4 IL2 IL13 CCL7 CCL5

Molecular functions related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.5 IL5 IL4 IL2
2 cytokine receptor binding GO:0005126 9.37 IL4 IL13
3 chemokine activity GO:0008009 9.33 CCL7 CCL5 CCL11
4 CCR1 chemokine receptor binding GO:0031726 9.26 CCL7 CCL5
5 cytokine activity GO:0005125 9.17 IL5 IL4 IL2 IL13 CCL7 CCL5
6 CCR chemokine receptor binding GO:0048020 9.13 CCL7 CCL5 CCL11

Sources for Onchocerciasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....